Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2023 - 2026)

Neuphoria Therapeutics (NEUP) has 4 years of Other Accumulated Expenses data on file, last reported at $169666.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $169666.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169666.0 (changed N/A YoY) and the FY2025 annual result came in at $278149.0, down 10.61% from the prior year.
• Other Accumulated Expenses grew to $169666.0 in Q1 2026 per NEUP's latest filing, from $28009.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $311172.0 in Q2 2024 and bottomed at $28009.0 in Q4 2025.
• The 4-year median for Other Accumulated Expenses is $95338.5 (2024), against an average of $131084.8.
• The widest annual swing landed in 2024, when Other Accumulated Expenses jumped 689.68%; it then fell 11.36% in 2025.
• Tracing NEUP's Other Accumulated Expenses over 4 years: stood at $39405.0 in 2023, then dropped by 19.81% to $31600.0 in 2024, then slipped by 11.36% to $28009.0 in 2025, then surged by 505.76% to $169666.0 in 2026.
• Per Business Quant, the three latest NEUP Other Accumulated Expenses figures stand at $169666.0 (Q1 2026), $28009.0 (Q4 2025), and $112028.0 (Q3 2025).

Peer Comparison